Time to address quality control processes applied to antibody testing for infectious diseases

被引:16
作者
Dimech, Wayne J. [1 ]
Vincini, Giuseppe A. [2 ]
Plebani, Mario [3 ]
Lippi, Giuseppe [4 ]
Nichols, James H. [5 ]
Sonntag, Oswald [6 ]
机构
[1] Natl Serol Reference Lab Australia, 4th Floor Healy Bldg,41 Victoria Parade, Fitzroy, Vic 3065, Australia
[2] Natl Serol Reference Lab, Melbourne, Vic, Australia
[3] Univ Hosp Padova, Padua, Italy
[4] Univ Verona, Dept Clin Biochem, Verona, Italy
[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[6] Sci Consultant, Eichenau, Germany
关键词
clinical chemistry; infectious disease serology; recommendations; third party controls; quality control; SEROLOGICAL ASSAYS; CLINICAL-CHEMISTRY; LIMITATIONS;
D O I
10.1515/cclm-2022-0986
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
As testing for infectious diseases moves from manual, biological testing such as complement fixation to high throughput automated autoanalyzer, the methods for controlling these assays have also changed to reflect those used in clinical chemistry. However, there are many differences between infectious disease serology and clinical chemistry testing, and these differences have not been considered when applying traditional quality control methods to serology. Infectious disease serology, which is highly regulated, detects antibodies of varying classes and to multiple and different antigens that change according to the organisms' genotype/serotype and stage of disease. Although the tests report a numerical value (usually signal to cut-off), they are not measuring an amount of antibodies, but the intensity of binding within the test system. All serology assays experience lot-to-lot variation, making the use of quality control methods used in clinical chemistry inappropriate. In many jurisdictions, the use of the manufacturer-provided kit controls is mandatory to validate the test run. Use of third-party controls, which are highly recommended by ISO 15189 and the World Health Organization, must be manufactured in a manner whereby they have minimal lot-to-lot variation and at a level where they detect exceptional variation. This paper outlines the differences between clinical chemistry and infectious disease serology and offers a range of recommendations when addressing the quality control of infectious disease serology.
引用
收藏
页码:205 / 212
页数:8
相关论文
共 31 条
[1]  
Andreis Elisabeth, 2014, J Diabetes Sci Technol, V8, P508, DOI 10.1177/1932296814523886
[2]   Revision of the "Guideline of the German Medical Association on Quality Assurance in Medical Laboratory Examinations - Rili-BAEK" (unauthorized translation) [J].
不详 .
LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE, 2015, 39 (01) :26-69
[3]  
[Anonymous], 2017, Off. J. Eur. Union, P1
[4]  
Australian Government, CLASS IVD MED DEV
[5]   Statistical validation of reagent lot change in the clinical chemistry laboratory can confer insights on good clinical laboratory practice [J].
Cho, Min-Chul ;
Kim, So Young ;
Jeong, Tae-Dong ;
Lee, Woochang ;
Chun, Sail ;
Min, Won-Ki .
ANNALS OF CLINICAL BIOCHEMISTRY, 2014, 51 (06) :688-694
[6]  
CLSI, 2011, EP23A CLIN LAB STAND
[7]  
CLSI, CLSI GUIDELINE 2016
[8]   Comprehensive quality control programme for serology and nucleic acid testing using an Internet-based application [J].
Dimech, W ;
Walker, S ;
Jardine, D ;
Read, S ;
Smeh, K ;
Karakaltsas, M ;
Dent, B ;
Dax, EM .
ACCREDITATION AND QUALITY ASSURANCE, 2004, 9 (03) :148-151
[9]   The Standardization and Control of Serology and Nucleic Acid Testing for Infectious Diseases [J].
Dimech, Wayne .
CLINICAL MICROBIOLOGY REVIEWS, 2021, 34 (04)
[10]   Determination of quality control limits for serological infectious disease testing using historical data [J].
Dimech, Wayne ;
Vincini, Giuseppe ;
Karakaltsas, Marina .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2015, 53 (02) :329-336